0001578563-24-000203.txt : 20240415 0001578563-24-000203.hdr.sgml : 20240415 20240415180306 ACCESSION NUMBER: 0001578563-24-000203 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240411 FILED AS OF DATE: 20240415 DATE AS OF CHANGE: 20240415 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Singleton Mark Leonard CENTRAL INDEX KEY: 0001914936 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37844 FILM NUMBER: 24845692 MAIL ADDRESS: STREET 1: C/O BIOVENTUS INC. STREET 2: 4721 EMPEROR BOULEVARD, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bioventus Inc. CENTRAL INDEX KEY: 0001665988 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 810980861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: (919) 474-6700 MAIL ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27703 4 1 wk-form4_1713218576.xml FORM 4 X0508 4 2024-04-11 0 0001665988 Bioventus Inc. BVS 0001914936 Singleton Mark Leonard 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 0 1 0 0 SVP & CFO 1 Class A Common Stock 2024-04-11 4 S 0 4000 4.75 D 34665 D Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 10, 2024 pursuant to a standing 10b5-1 instruction adopted on April 10, 2023. The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $4.53 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. /s/ Anthony D'Adamio, Attorney-in-Fact 2024-04-15